Related Experiment Videos
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa
C de la Salle1, J L Charmantier, C Ravanat
1INSERM U 311, Centre Régional de Transfusion Sanguine, Strasbourg, France.
Nouvelle Revue Francaise D'Hematologie
|January 1, 1993
Summary
Factor IX Strasbourg 2, a severe hemophilia B mutation, shows reduced carboxylation and delayed activation. This mutant protein circulates with an attached propeptide, impacting its function.
Area of Science:
- Biochemistry
- Molecular Biology
- Genetics
Background:
- Severe hemophilia B is linked to mutations in the Factor IX gene.
- Understanding these mutations is crucial for developing targeted therapies.
Observation:
- Factor IX Strasbourg 2 exhibits a higher molecular weight than normal Factor IX.
- A G-to-A mutation at gene position 6365 results in Arg to Gln substitution at propeptide position -4.
Findings:
- The mutant Factor IX Strasbourg 2 displays significantly reduced calcium binding and approximately 50% carboxylation compared to normal Factor IX.
- Activation of Factor IX Strasbourg 2 by Factor XIa is delayed, but its capacity to activate Factor X post-cleavage remains normal.
Implications:
- The characterization of Factor IX Strasbourg 2 provides insights into the structure-function relationship of Factor IX.
- This detailed molecular understanding can inform the development of novel therapeutic strategies for hemophilia B patients with similar mutations.